Profile data is unavailable for this security.
About the company
Anixa Biosciences, Inc. is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. The Company's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. The Company is engaged in the development of vaccines for the treatment or prevention of triple negative breast cancer and other breast cancers which express the a-lactalbumin protein. Its vaccine technologies are focused on immunizing against retired proteins that have been found to be expressed in certain forms of cancer.
- Revenue in USD (TTM)0.00
- Net income in USD-10.93m
- Incorporated1982
- Employees4.00
- LocationAnixa Biosciences Inc3150 Almaden Expy Ste 250SAN JOSE 95118United StatesUSA
- Phone+1 (408) 708-9808
- Fax+1 (302) 655-5049
- Websitehttps://www.anixa.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pyxis Oncology Inc | 2.82m | -97.09m | 91.53m | 44.00 | -- | 1.33 | -- | 32.46 | -1.58 | -1.58 | 0.0457 | 1.11 | 0.0187 | -- | -- | 64,090.91 | -64.53 | -47.22 | -74.33 | -53.45 | 0.00 | -- | -3,442.77 | -2,233.63 | -- | -- | 0.0006 | -- | -- | -- | -4.80 | -- | -- | -- |
| Codexis Inc | 52.93m | -63.95m | 92.13m | 188.00 | -- | 2.39 | -- | 1.74 | -0.7514 | -0.7514 | 0.6238 | 0.4269 | 0.389 | 5.42 | 4.03 | 281,553.20 | -47.00 | -21.95 | -58.53 | -26.20 | 79.31 | 76.67 | -120.82 | -49.88 | 4.02 | -- | 0.5076 | -- | -15.39 | -2.82 | 14.38 | -- | 2.91 | -- |
| TuHURA Biosciences Inc | 0.00 | -43.77m | 92.30m | 19.00 | -- | 4.72 | -- | -- | -1.60 | -1.60 | 0.00 | 0.3273 | 0.00 | -- | -- | 0.00 | -286.97 | -- | -456.76 | -- | -- | -- | -- | -- | -- | -9.01 | 0.0286 | -- | -- | -- | -- | -- | -- | -- |
| Ibio Inc | 300.00k | -24.74m | 92.92m | 20.00 | -- | 1.43 | -- | 309.74 | -1.26 | -1.26 | 0.0112 | 1.88 | 0.007 | -- | -- | 15,000.00 | -57.47 | -30.90 | -65.55 | -37.76 | -- | -- | -8,245.67 | -2,374.12 | -- | -- | 0.00 | -- | 77.78 | -24.57 | -19.00 | -- | -57.50 | -- |
| Cognition Therapeutics Inc | 0.00 | -27.99m | 93.57m | 25.00 | -- | 2.56 | -- | -- | -0.4816 | -0.4816 | 0.00 | 0.4138 | 0.00 | -- | -- | 0.00 | -78.86 | -59.00 | -108.44 | -75.05 | -- | -- | -- | -- | -- | -3,450.08 | 0.00 | -- | -- | -- | -31.73 | -- | -51.16 | -- |
| Dogwood Therapeutics Inc | 0.00 | -39.98m | 93.89m | 12.00 | -- | -- | -- | -- | -24.92 | -24.92 | 0.00 | 33.75 | 0.00 | -- | -- | 0.00 | -81.05 | -52.48 | -84.58 | -55.93 | -- | -- | -- | -- | -- | -178.51 | 0.00 | -- | -- | -- | -142.90 | -- | -- | -- |
| Kazia Therapeutics Ltd (ADR) | 80.84k | -14.68m | 94.47m | 12.00 | -- | -- | -- | 1,168.68 | -12.31 | -12.31 | 0.0563 | -3.64 | 0.0083 | -- | 0.0571 | -- | -149.76 | -64.49 | -- | -99.77 | -- | -- | -18,159.65 | -573.31 | -- | -- | -- | -- | -95.09 | 11.58 | 22.69 | -- | -- | -- |
| Citius Oncology Inc | 3.94m | -23.64m | 95.34m | -- | -- | 1.57 | -- | 24.17 | -0.3102 | -0.3102 | 0.0511 | 0.6889 | 0.0394 | 0.0426 | -- | -- | -23.58 | -- | -42.08 | -- | 79.99 | -- | -599.28 | -- | 0.3245 | -112.34 | 0.0611 | -- | -- | -- | -17.08 | -- | -- | -- |
| PMV Pharmaceuticals Inc | 0.00 | -82.71m | 95.78m | 63.00 | -- | 0.7883 | -- | -- | -1.58 | -1.58 | 0.00 | 2.28 | 0.00 | -- | -- | 0.00 | -46.29 | -21.46 | -49.90 | -22.32 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 14.87 | -- | 43.14 | -- |
| Biomea Fusion Inc | 0.00 | -95.71m | 96.86m | 42.00 | -- | 5.22 | -- | -- | -2.39 | -2.39 | 0.00 | 0.2625 | 0.00 | -- | -- | 0.00 | -115.59 | -62.24 | -156.30 | -68.84 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -18.06 | -- | -- | -- |
| aTyr Pharma Inc | 190.00k | -75.12m | 97.01m | 56.00 | -- | 1.21 | -- | 510.56 | -0.8345 | -0.8345 | 0.0021 | 0.8188 | 0.0019 | -- | 0.1323 | 3,392.86 | -75.78 | -47.98 | -88.99 | -54.91 | -- | -- | -39,540.53 | -978.90 | -- | -- | 0.0127 | -- | -33.43 | -11.05 | -27.06 | -- | -3.83 | -- |
| Anixa Biosciences Inc | 0.00 | -10.93m | 98.80m | 4.00 | -- | 6.45 | -- | -- | -0.3369 | -0.3369 | 0.00 | 0.4593 | 0.00 | -- | -- | 0.00 | -58.55 | -47.85 | -62.09 | -49.81 | -- | -- | -- | -8,381.30 | -- | -- | 0.00 | -- | -- | -- | 12.96 | -- | -- | -- |
| Precision BioSciences Inc | 698.00k | -83.60m | 99.15m | 67.00 | -- | 3.15 | -- | 142.04 | -8.40 | -8.40 | 0.0695 | 1.38 | 0.0057 | -- | 0.9001 | 6,462.96 | -67.76 | -26.22 | -76.07 | -33.68 | -- | -- | -11,977.36 | -87.80 | -- | -190.84 | 0.5736 | -- | 40.98 | 25.30 | 116.85 | -- | -59.31 | -- |
| Gossamer Bio Inc | 44.05m | -156.16m | 99.20m | 144.00 | -- | -- | -- | 2.25 | -0.6872 | -0.6872 | 0.1939 | -0.356 | 0.1574 | -- | 5.57 | 305,909.70 | -55.80 | -51.30 | -69.95 | -58.28 | -- | -- | -354.50 | -822.21 | -- | -15.04 | 1.71 | -- | -- | -- | 68.56 | -- | -- | -- |
| Goldenwell Biotech Inc | 62.50k | -75.13k | 103.95m | -- | -- | -- | -- | 1,663.20 | -0.0007 | -0.0007 | 0.0006 | -0.001 | 0.3126 | 0.00 | -- | -- | -37.58 | -95.49 | -41.82 | -110.12 | 100.00 | 52.18 | -120.21 | -2,064.27 | 1.16 | -4.11 | 124.14 | -- | -92.39 | -13.55 | -12.05 | -- | -- | -- |
| Gain Therapeutics Inc | 0.00 | -19.39m | 104.23m | 23.00 | -- | 16.50 | -- | -- | -0.6364 | -0.6364 | 0.00 | 0.1643 | 0.00 | -- | -- | 0.00 | -153.07 | -79.58 | -234.03 | -95.32 | -- | -- | -- | -19,975.78 | -- | -33.79 | 0.067 | -- | -100.00 | -- | 8.34 | -- | 10.39 | -- |
Data as of Mar 03 2026. Currency figures normalised to Anixa Biosciences Inc's reporting currency: US Dollar USD
12.35%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2025 | 1.26m | 3.77% |
| Laird Norton Wetherby Wealth Management LLCas of 31 Dec 2025 | 588.03k | 1.76% |
| D.A. Davidson & Co. (Investment Management)as of 31 Dec 2025 | 539.27k | 1.62% |
| UBS Financial Services, Inc.as of 31 Dec 2025 | 418.09k | 1.25% |
| Geode Capital Management LLCas of 31 Dec 2025 | 350.92k | 1.05% |
| Susquehanna Financial Group LLLPas of 31 Dec 2025 | 252.07k | 0.76% |
| Mission Wealth Management LPas of 31 Dec 2025 | 206.90k | 0.62% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 191.07k | 0.57% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 159.04k | 0.48% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 158.26k | 0.47% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
